The physician-led clinical trial is planned for 60 cases in 3 years targeting the treatment of intermittent claudication (muscle pain). PI is Professor Yonemitsu YOSHIWA, and the Sendai-virus based vector from DNAVec is being used.

Nikkei Biotech news release, Jan. 6, 2015